UMMS, RXi receive MLSC grant to develop RNAi therapeutics for ALS
 

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted and immunotherapy technologies, today announced that the company's proposed research collaboration with the University of Massachusetts Medical School has been selected for Cooperative Research Matching Grant funding by the Massachusetts Life Sciences Center.

More...